A single‐center report of COVID‐19 disease course and management in liver transplanted pediatric patients
Open Access
- 2 June 2021
- journal article
- research article
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (7) , e14061
Abstract
Background: In 2019, SARS‐CoV‐2 causing COVID‐19 emerged. Severe COVID‐19 symptoms may evolve by virtue of hyperactivation of the immune system. Equally, immunocompromised patients may be at increased risk to develop COVID‐19. However, treatment guidelines for children following liver transplantation are elusive.Methods: As a liver transplantation center, we diagnosed and followed up 10 children (male/female: 8/2) with a median age of 8.5 years (IQR: 5.2–11.0), with COVID‐19 post‐liver transplant between March 2019 and December 2020. COVID‐19 diagnosis was based on PCR test and or florid X‐ray findings compatible with COVID‐19 in the absence of other cause. We retrospectively collected clinical and laboratory data from electronic patient records following written consent from patients/parents.Results: Nine patients were diagnosed as definitive (PCR positive) with one patient being diagnosed as probable COVID‐19. Seven patients recovered without any support whereas three were admitted for non‐invasive oxygenation. Lymphopenia and/or high levels of serum IL‐6 were detected in four patients. Six patients mounted anti‐SARS‐CoV‐2 antibodies at median 30 days (IQR: 26.5–119.0) following COVID‐19 diagnosis. Antibiotic therapy, favipiravir, anakinra, and IVIG were used as treatment in 4,1,1 and 2 patients, respectively. Furthermore, we kept the tacrolimus with or without everolimus but stopped MMF in 2 patients. Importantly, liver allograft function was retained in all patients.Conclusions: We found that being immunocompromised did not affect disease severity nor survival. Stopping MMF yet continuing with tacrolimus was an apt treatment modality in these patients.Keywords
This publication has 33 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Coronavirus infections and immune responsesJournal of Medical Virology, 2020
- Characteristics and Outcomes of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised StateJournal of the Pediatric Infectious Diseases Society, 2018
- Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including AlisporivirVirus Research, 2014
- Suppression of Coronavirus Replication by Cyclophilin InhibitorsViruses, 2013
- Infections in Pediatric Solid Organ Transplant RecipientsJournal of the Pediatric Infectious Diseases Society, 2012
- Pattern of bacterial and fungal infections in the first 3 months after pediatric living donor liver transplantation: An 11-year single-center experienceLiver Transplantation, 2011
- Effect of immunosuppressive agents FK506 and cyclosporin and steroids on the expression of IL-6 and its receptor by stimulated lymphocytes and monocytesTransplant International, 1994